Article

Regulation of Hepatitis C virus replication and gene expression by the MAPK-ERK pathway

Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
Virologica Sinica 10/2012; 27(5). DOI: 10.1007/s12250-012-3257-6

ABSTRACT The mitogen activated protein kinases-extracellular signal regulated kinases (MAPK-ERK) pathway is involved in regulation of multiple cellular processes including the cell cycle. In the present study using a Huh7 cell line Con1 with an HCV replicon, we have shown that the MAPK-ERK pathway plays a significant role in the modulation of HCV replication and protein expression and might influence IFN-α signalling. Epithelial growth factor (EGF) was able to stimulate ERK activation and decreased HCV RNA load while a MAPK-ERK pathway inhibitor U0126 led to an elevated HCV RNA load and higher NS5A protein amounts in Con1 cells. It could be further demonstrated that the inhibition of the MAPK-ERK pathway facilitated the translation directed by the HCV internal ribosome entry site. Consistently, a U0126 treatment enhanced activity of the HCV reporter replicon in transient transfection assays. Thus, the MAPK-ERK pathway plays an important role in the regulation of HCV gene expression and replication. In addition, cyclin-dependent kinases (CDKs) downstream of ERK may also be involved in the modulation of HCV replication since roscovitine, an inhibitor of CDKs had a similar effect to that of U0126. Modulation of the cell cycle progression by cell cycle inhibitor or RNAi resulted consistently in changes of HCV RNA levels. Further, the replication of HCV replicon in Con1 cells was inhibited by IFN-α. The inhibitory effect of IFN-α could be partly reversed by pre-incubation of Con-1 cells with inhibitors of the MAPK-ERK pathway and CDKs. It could be shown that the MAPK-ERK inhibitors are able to partially modulate the expression of interferon-stimulated genes.

Download full-text

Full-text

Available from: Zhongji Meng, Dec 28, 2013
1 Follower
 · 
212 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to evaluate the anti-hepatitis C virus (HCV) activity of andrographolide, a diterpenoid lactone extracted from Andrographis paniculata, and to identify the signaling pathway involved in its antiviral action. Using HCV replicon and HCVcc infectious systems, we identified anti-HCV activity of andrographolide by measuring protein and RNA levels. A reporter activity assay was used to determine transcriptional regulation of anti-HCV agents. A specific inhibitor and short hairpin RNAs were used to investigate the mechanism responsible for andrographolide action against HCV replication. Andrographolide time- and dose-dependently suppressed HCV replication in HCV replicon and HCVcc infectious systems with EC50 values of 6 ± 0.5 μM and 5.1 ± 0.7 μM, respectively. Andrographolide exhibited a significant synergistic effect in combination with interferon-alpha, an inhibitor targeting HCV NS3/4A protease (telaprevir), or NS5B polymerase (PSI-7977). Andrographolide upregulated heme oxygenase 1 (HO-1) expression, leading to increased amounts of its metabolite biliverdin against HCV replication by promoting antiviral IFN responses and inhibiting NS3/4A protease activity. Conversely, these antiviral effects were abrogated by an HO-1-specific inhibitor or HO-1 gene knockdown, indicating that HO-1 induction contributed to the anti-HCV activity of andrographolide. Andrographolide-elevated HO-1 expression against HCV replication was associated with p38 mitogen-activated protein kinase-mediated induction of nuclear factor erythroid 2-related factor 2 (Nrf2). Our results reveal andrographolide as a potential supplement for the control of HCV replication and suggest that targeting the Nrf2-HO-1 signaling pathway might be a promising strategy for drug development.
    British Journal of Pharmacology 10/2013; DOI:10.1111/bph.12440 · 4.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interfering with cellular signal transduction pathways is a common strategy used by many viruses to create a propitious intracellular environment for an efficient replication. Our group has been studying cellular signalling pathways activated by the orthopoxviruses Vaccinia (VACV) and Cowpox (CPXV) and their significance to viral replication. In the present study our aim was to investigate whether the GTPase Rac1 was an upstream signal that led to the activation of MEK/ERK1/2, JNK1/2 or Akt pathways upon VACV or CPXV' infections. Therefore, we generated stable murine fibroblasts exhibiting negative dominance to Rac1-N17 to evaluate viral growth and the phosphorylation status of ERK1/2, JNK1/2 and Akt. Our results demonstrated that VACV replication, but not CPXV, was affected in dominant-negative (DN) Rac1-N17 cell lines in which viral yield was reduced in about 10-fold. Viral late gene expression, but not early, was also reduced. Furthermore, our data showed that Akt phosphorylation was diminished upon VACV infection in DN Rac1-N17 cells, suggesting that Rac1 participates in the phosphoinositide-3 kinase pathway leading to the activation of Akt. In conclusion, our results indicate that while Rac1 indeed plays a role in VACV biology, perhaps another GTPase may be involved in CPXV replication.
    Memórias do Instituto Oswaldo Cruz 08/2013; 108(5):554-62. DOI:10.1590/S0074-02762013000500004 · 1.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to find novel antiviral agents, a series of allosteric MEK1 inhibitors were designed and synthesized. Based on docking results, multiple optimizations were made on the coumarin scaffold. Some of the derivatives showed excellent MEK1 binding affinity in the appropriate enzymatic assays and displayed obvious inhibitory effects on the ERK pathway in a cellular assay. These compounds also significantly inhibited virus (EV71) replication in HEK293 and RD cells. Several compounds showed potential as agents for the treatment of viral infective diseases, with the most potent compound 18 showing an IC50 value of 54.57 nM in the MEK1 binding assay.
    Molecules 05/2013; 18(5):6057-6091. DOI:10.3390/molecules18056057 · 2.42 Impact Factor